Ropanicant (SUVN-911), α4β2 Receptor Antagonist for the Treatment of Depressive Disorders

Phase-2 PoC Study Initiation by Q2 2022



Suven Life Sciences Ltd Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad-500 034, India. Contacts: jasti@suven.com, nvsrk@suven.com



Ropanicant: Non-Clinical Overview

- Novel, potent and selective α4β2 nicotinic acetylcholine receptor (nAChR) antagonist
- Demonstrated excellent ADME properties with no drug-drug interaction liability
- Excellent oral bioavailability and brain penetration
- Shows robust efficacy in various animal models of depression
- Robust increase in serotonin levels in cortex which may partly explain the antidepressant property
- Addresses major limitations of existing MDD therapeutics by offering rapid onset of action, procognitive effects and no sexual dysfunction
- Demonstrated excellent safety margin in all long term toxicity studies
- Non-mutagenic and non-clastogenic
- Non-teratogenic



Ropanicant: Clinical Overview

- Safe and well tolerated in healthy adult male subjects with dose dependent pharmacokinetics
- Projected human efficacy concentrations achieved in Phase-1 study
- Predictive biomarker available for clinical evaluation
- Food, gender and age has no effect on pharmacokinetics



Ropanicant: Medicinal Chemistry & Intellectual Property

Medicinal Chemistry

Ropanicant is innovatively designed, best in class clinical candidate*

- BCS class I non-hygroscopic crystalline hydrochloride salt and stable in all storage conditions
- Favorable physicochemical and biopharmaceutical properties
- Log P and pKa values of 1.9 and 8.9 respectively

Intellectual Property

• Patents have been granted in all major world markets

*Nirogi et al., J. Med. Chem., 63, 2020, 2833-2853 (doi: 10.1021/acs.jmedchem.9b00790)



Ropanicant: In Vitro Efficacy

In Vitro Potency and Selectivity

- Effectively binds at $\alpha 4\beta 2$ ion channel with a Ki value of 31.1 nM
- Exhibited dose dependent blockade of nAChR α4β2 receptor currents induced by acetylcholine in whole cell patch clamp assay exhibiting antagonist property
- No inter species variation in binding to $\alpha 4\beta 2$ receptor from mouse, rat and human
- Exhibited ~ 130 fold selectivity towards α3β4 and has a minimal binding against over 70 target sites (at 10 µM) comprising GPCRs, transporters, brain/gut peptides, enzymes, kinases, prostaglandins, ion channels including closely related α-Bungarotoxin sensitive neuronal nicotinic acetylcholine receptors (α7)




Ropanicant: ADME Profile

- Has high permeability and is not a P-gp substrate
- Good unbound fractions in plasma and brain
- Moderate metabolism in rat, dog, monkey and human liver microsomes
- Well absorbed into systemic circulation with excellent oral bioavailability
- Good brain penetration (brain to plasma ratio ~ 2.0)
- No drug-drug interaction liability
- Similar metabolites across species (rat, dog and human) and no unique metabolite observed




Receptor Occupancy



Dose-dependent receptor occupancy

Good correlation with unbound concentrations at target site

In Vivo Efficacy




Robust non-clinical efficacy

Marked antidepressant effects in forced swim test




Dominant submissive assay



Faster onset of action

Antidepressant effects within a week of treatment






Basis for antidepressant effects

Modulation of cortical monoamines




Procognitive Effects



Promotes cognition


A value addition in therapy for depressive disorders

Acetylcholine Modulation



Basis for procognitive effects Modulation of cortical acetylcholine





No effects on sexual functions

Differentiated from conventional antidepressants

No abuse or addiction liabilities

Well differentiated from nicotine



Ropanicant: Summary of Safety Pharmacology

CNS Safety

- No CNS stimulant or depressant effects upon repeated administration (Open field assay)
- No addiction liability (Behavioral sensitization assay)
- No effect on skeletal muscles (Rota rod assay)
- No significant effect in rats at therapeutic dose range (Modified Irwin's test)

Cardiovascular Safety

- hERG channel: IC_{50} value >10 μ M in patch clamp assay
- ECG (QT / QTc) & Blood pressure: No significant effect on the cardiovascular parameters in conscious dogs.

Respiratory Safety

• No significant effect on respiratory parameters in rats at therapeutic dose range

Gastrointestinal Safety

• No significant effect on gastrointestinal system



Ropanicant: Summary of Non-Clinical Safety

Non-Clinical Safety Evaluation

- The safety of Ropanicant has been well established following single and repeat dose oral administration up to 28- day, 6- month and 9- month duration in mice, rats, and dogs, respectively; Ropanicant has a wide margin of safety
- Ropanicant was found to be non-mutagenic and non-clastogenic in in-vitro/in-vivo genotoxicity studies
- Ropanicant did not show teratogenic potential when tested in rats and rabbits



Ropanicant: Clinical Profile (Phase-1)

Ropanicant has been evaluated for its safety, tolerability, and pharmacokinetics under US-IND (NCT03155503) following single and multiple oral administration in healthy subjects

Effect of food, gender and age on the pharmacokinetics of Ropanicant in healthy subjects has also been evaluated (NCT03551288)

- Well tolerated after single and multiple oral administrations up to 14 days
- No serious adverse events reported by any subject and no subject withdrawn from the study due to the treatment
- Rapid oral absorption
- Exposures in healthy subjects are more than dose proportional at tested doses
- Projected efficacious concentrations achieved in Phase-1 study
- Food, gender and age has no effects on human pharmacokinetics of Ropanicant
- Active IND at US FDA